Resultados

Labiana, the pharmaceutical company specializing in both animal and human health and listed on BME Growth, returns this year to the MedCap Forum—the key event for European small and mid-cap investors listed in Spain—to present its business model and expansion plan to interested investors.

Labiana, the pharmaceutical laboratory specializing in both animal and human health and listed on BME Growth, will present its latest additions to its product portfolio at the ANEMBE International Congress of Bovine Medicine, taking place from May 28 to 30 in Vitoria. Among the highlights is a new antibiotic with zero milk withdrawal time in dairy cattle.

Labiana closed the 2024 fiscal year with revenues of €66.26 million, representing a 13.3% increase compared to the previous year.

Labiana divests its Serbian subsidiary through a capital increase agreement

Labiana, el primer laboratorio veterinario español cotizado en Bolsa, ha hecho público su informe de resultados mostrando un incremento en su facturación en 2023

Labiana, el primer laboratorio veterinario español cotizado en Bolsa, ha hecho público su informe de resultados mostrando un incremento en su facturación en 2023